

Modern Slavery Act Statement 2022-2023

This statement is made by Serge Kemps, Chief Executive Officer of the UK on behalf of Nipro Diagnostics UK and Nipro Medical UK.

We oppose Slavery and human trafficking in all its forms. We are committed to improving our practices to combat slavery and human trafficking.

We are a manufacturer of safe and accurate medical equipment in the medical and pharmaceutical sector. We are a part of the Nipro group of companies (Group), and our ultimate parent company is Nipro Corporation which has its head office in Japan. The Group has over 35.000 employees worldwide and it operates in 56 countries.

The Group employs 30 employees in the UK. There is a very low risk that employees do not have the right to work in the UK, or that they are paid less than the minimum statutory pay provisions. Our human resources, audit and compliance teams are trained to minimise such risks.

To ensure a high level of understanding of the risks of modern slavery and human trafficking in our supply chains and our business, we provide training to our staff. Our whistleblowing policy encourages staff to report any relevant concerns, including concerns related to slavery or human trafficking. Our business is organised into several business units: engineering and technology, pharmaceutical, and packaging.

Our supply chains include sourcing raw materials used in our manufacturing processes, and supplying our products to other pharmaceutical manufacturers, pharmacies, and hospitals. We have factories in Europe, Asia, Africa, and South America, and have suppliers and customers all over the globe. We evaluate the risks of modern slavery and human trafficking on an ongoing basis. Given that we operate on a global scale, we have identified certain parts of Asia and Africa as carrying a higher potential risk for modern slavery. These areas are monitored by our audit and compliance teams.



Serge Kemps
CEO Nipro Medical Europe

